Recent News

• 09.02.2025 - Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting
• 09.02.2025 - Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting
• 09.02.2025 - Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting
• 08.11.2025 - Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025
• 08.11.2025 - Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025
• 08.11.2025 - Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025
• 08.07.2025 - Al Kucharchuk
• 08.07.2025 - Al Kucharchuk
• 08.05.2025 - Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients
• 08.05.2025 - Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients

Recent Filings

• 09.02.2025 - 8-K Current report
• 08.20.2025 - 8-K Current report
• 08.19.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
• 08.11.2025 - ARS Annual Report to Security Holders
• 08.08.2025 - DEF 14A Other definitive proxy statements
• 08.08.2025 - 8-K Current report
• 08.05.2025 - 8-K Current report
• 08.05.2025 - 3 Initial statement of beneficial ownership of securities